Home/Pipeline/CARG-201

CARG-201

Chronic Hepatitis B (CHB)

Pre-clinicalActive

Key Facts

Indication

Chronic Hepatitis B (CHB)

Phase

Pre-clinical

Status

Active

Company

CaroGen

About CaroGen

CaroGen is a private, pre-clinical-stage biotech developing immunotherapies using its innovative AVIDIO platform, an RNA-based artificial virus technology capable of delivering multiple transgenes to elicit broad immune responses. Its pipeline features two late-stage pre-clinical candidates: CARG-2020 for ovarian cancer and CARG-201 for chronic hepatitis B (CHB). The company is backed by significant non-dilutive funding from the NIH and DoD, exceeding $16 million for its HBV program, and holds a broad patent portfolio covering composition of matter and methods of use.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Chronic Hepatitis B (CHB) Drugs

Drug	Company	Phase	Status
Anti-HBVxCD3	Ancora Bio	Preclinical	Active
Peginterferon-based therapies	Amoytop Biotech	Clinical	Multiple ongoing programs
VIR-2218 + VIR-3434	Vir Biotechnology	Phase 2	Active
Pevifoscorvir sodium (ALG-000184)	Aligos Therapeutics	Phase 2	Active
ALG-125755	Aligos Therapeutics	Phase 1	Status Unclear (Deprioritized)